Dare Bioscience, Inc. Contracts & Agreements

Purchase Agreement, dated October 21, 2024, by and between Daré Bioscience, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on October 21, 2024)

Registration Rights Agreement, dated October 21, 2024, by and between Daré Bioscience, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on October 21, 2024)

Amendment No. 3 to Grant Agreement between Dar Bioscience, Inc. and the Bill & Melinda Gates Foundation, dated as of April 18, 2024 (Filed With SEC on August 12, 2024)

Amended and Restated Non-Employee Director Compensation Policy (as amended on April 2024) (Filed With SEC on August 12, 2024)

Amendment No. 2 to Employment Agreement between Dar Bioscience, Inc. and Sabrina Martucci Johnson, dated as of May 20, 2024 (Filed With SEC on August 12, 2024)

Dar Bioscience, Inc. Change in Control Policy (as amended on April 29, 2024) (Filed With SEC on August 12, 2024)

Dar Bioscience, Inc (Filed With SEC on August 12, 2024)

Consulting Agreement by and between Dar Bioscience, Inc. and Lisa Walters-Hoffert, dated as of January 26, 2024 (Filed With SEC on May 14, 2024)

Form of common stock purchase warrants issued on December 21, 2023 (Filed With SEC on March 28, 2024)

Royalty Interest Financing Agreement entered into as of December 21, 2023 between Dare Bioscience, Inc. and United in Endeavor, LLC (Filed With SEC on March 28, 2024)

First Amendment to License Agreement by and between Organon International GmbH and Dar Bioscience, Inc., entered into as of July 4, 2023 (Filed With SEC on November 9, 2023)

Dar Bioscience, Inc. Performance Bonus Plan, as amended (Filed With SEC on November 9, 2023)

Form of Warrant (August 2023) (Filed With SEC on August 30, 2023)

Form of Securities Purchase Agreement (August 2023) (Filed With SEC on August 30, 2023)

Sales Agreement, dated as of March 31, 2023, between Stifel, Nicolaus & Company, Incorporated, Cantor Fitzgerald & Co. and Dar Bioscience, Inc (Filed With SEC on March 31, 2023)

Amendment No. 3 to the Amended and Restated Exclusive License Agreement, effective as of February 13, 2017, by and among Fred Mermelstein, Ph.D., and Janet Chollet, M.D., Pear... (Filed With SEC on March 30, 2023)

Dar Bioscience, Inc. 2022 Stock Incentive Plan (Filed With SEC on June 24, 2022)

Form of Incentive Stock Option Agreement for grants under the Dar Bioscience, Inc. 2022 Stock Incentive Plan (Filed With SEC on June 24, 2022)

Form of Nonstatutory Stock Option Agreement for grants under the Dar Bioscience, Inc. 2022 Stock Incentive Plan (Filed With SEC on June 24, 2022)

Exclusive license agreement by and between Organon International GmbH and Dar Bioscience, Inc., dated as of March 31, 2022 (Filed With SEC on May 12, 2022)

Consent, Waiver and Stand-By License Agreement, dated March 30, 2022, by and among TriLogic Pharma, LLC, and MilanaPharm LLC, Dare Bioscience, Inc., and Organon International GmbH (Filed With SEC on May 12, 2022)

Amended & Restated Non-Employee Director Compensation Policy (as amended through January 2022) (Filed With SEC on May 12, 2022)

Warrant Agreement to purchase shares of common stock of the registrant with Aquilo Partners, L.P., entered into as of October 16, 2016 (Filed With SEC on March 31, 2022)

Amendment to License Agreement effective as of September 21, 2021 by and among Dar Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC (Filed With SEC on November 10, 2021)

Cooperative Research and Development Agreement entered into as of July 8, 2021 between Dare Bioscience, Inc. and the Eunice Kennedy Schriver National Institutes of Child Health... (Filed With SEC on November 10, 2021)

Sales Agreement, dated as of (Filed With SEC on October 13, 2021)

Grant Agreement between Dar Bioscience, Inc. and the Bill & Melinda Gates Foundation effective as of June 30, 2021 (Filed With SEC on August 12, 2021)

Sales Agreement, dated as of April (Filed With SEC on April 8, 2021)

Dar Bioscience, Inc. Employment Offer Letter to John Fair, dated April 24, 2018 (Filed With SEC on January 5, 2021)

Dar Bioscience, Inc. Change in Control Policy (effective October 15, 2019) (Filed With SEC on January 5, 2021)

Amendment No. 1 to Employment Agreement between Dar Bioscience, Inc. and Sabrina Martucci Johnson dated as of March 9, 2020 (Filed With SEC on May 14, 2020)

Amendment No. 1 to Employment Agreement between Dar Bioscience, Inc. and Lisa Walters-Hoffert dated as of March 9, 2020 (Filed With SEC on May 14, 2020)

Purchase Agreement, dated April 22, 2020, by and between Dar Bioscience, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on April 23, 2020)

Registration Rights Agreement, dated April 22, 2020, by and between Dar Bioscience, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on April 23, 2020)

Description of securities of the registrant (Filed With SEC on March 27, 2020)

License Agreement dated as of January 10, 2020 between Bayer HealthCare LLC and Dar Bioscience, Inc (Filed With SEC on March 27, 2020)

Amendment No. 1 to Assignment Agreement entered into as of December 4, 2019 between Dar Bioscience, Inc. and Hammock Pharmaceuticals, Inc (Filed With SEC on March 27, 2020)

Amendment No. 2 to the License Agreement entered into as of December 3, 2019 between Dar Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC (Filed With SEC on March 27, 2020)

Dar Bioscience, Inc. Performance Bonus Plan (Filed With SEC on November 12, 2019)

Agreement and Plan of Merger, dated November 10, 2019, Dar Bioscience, Inc., MC Merger Sub, Inc., Microchips Biotech, Inc., and Shareholder Representative Services LLC, as the... (Filed With SEC on November 12, 2019)

Underwriting Agreement dated as of April 9, 2019, by and between Dar Bioscience, Inc. and Roth Capital Partners, LLC, as the representative for the underwriters named therein (Filed With SEC on April 9, 2019)

Assignment Agreement by and between Dar Bioscience, Inc. and Hammock Pharmaceuticals, Inc. effective as of December 5, 2018 (Filed With SEC on April 1, 2019)

First Amendment to the License Agreement effective as of December 5, 2018 by and among Dar Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC (Filed With SEC on April 1, 2019)

Form of Amendment to Warrant to Purchase Common Stock entered into as of June 27, 2018 (Filed With SEC on November 13, 2018)

Amendment No. 1 to Common Stock Sales Agreement, dated August 24, 2018, between Dar Bioscience, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on August 27, 2018)

Exclusive License Agreement made as April 24, 2018 by and between Juniper Pharmaceuticals, Inc., and Dar Bioscience, Inc (Filed With SEC on August 13, 2018)

Non-Employee Director Compensation Policy (as amended through April 9, 2018) (Filed With SEC on August 13, 2018)

Form of Incentive Stock Option Agreement for grants under the Dar Bioscience, Inc. Amended and Restated 2014 Stock Incentive Plan (Filed With SEC on August 13, 2018)

Form of Nonstatutory Stock Option Agreement for grants under the Dar Bioscience, Inc. Amended and Restated 2014 Stock Incentive Plan (Filed With SEC on August 13, 2018)

Amended and Restated Exclusive License Agreement, dated as of July 14, 2006, by and between Fred Mermelstein, Ph.D. and Janet Chollet, M.D., and Pear Tree Womens Health Care, Inc (Filed With SEC on August 13, 2018)

Amendment No. 1 to the Amended and Restated Exclusive License Agreement, dated as of October 10, 2007, by and among Fred Mermelstein, Ph.D. and Janet Chollet, M.D., and Pear Tree... (Filed With SEC on August 13, 2018)

Amendment No. 2 to the Amended and Restated Exclusive License Agreement, dated as of February 13, 2017, by and among Fred Mermelstein, Ph.D., and Janet Chollet, M.D., Pear Tree... (Filed With SEC on August 13, 2018)

Exclusive License Agreement, dated as of February 13, 2017, by and between GYN Holdings, Inc., a wholly owned subsidiary of Pear Tree Pharmaceuticals, Inc. and Bernadette Klamerus (Filed With SEC on August 13, 2018)

Exclusive License Agreement, dated as of September 15, 2017, by and between Fred Mermelstein, Ph.D., Janet Chollet, M.D., Pear Tree Pharmaceuticals, Inc., and Stephen C. Rocamboli (Filed With SEC on August 13, 2018)

Agreement and Plan of Merger, dated as of April 30, 2018, by and among Dar Bioscience, Inc., Dar Merger Sub, Inc., Pear Tree Pharmaceuticals, Inc., and Fred Mermelstein and... (Filed With SEC on August 13, 2018)

Dar Bioscience, Inc. Amended and Restated 2014 Stock Incentive Plan (Filed With SEC on July 12, 2018)

Specimen stock certificate evidencing the shares of common stock (Filed With SEC on March 28, 2018)

License and Collaboration Agreement dated February 11, 2018 between Dar Bioscience, Inc., Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC (Filed With SEC on March 28, 2018)

Amended and Restated 2015 Employee, Director and Consultant Equity Incentive Plan of Dar Bioscience Operations, Inc (Filed With SEC on March 28, 2018)

Form of Stock Option Agreement under the Amended and Restated 2015 Employee, Director and Consultant Equity Incentive Plan of Dar Bioscience Operations, Inc (Filed With SEC on March 28, 2018)

Underwriting Agreement, dated February 13, 2018, by and between Roth Capital Partners, LLC and the Registrant (Filed With SEC on February 13, 2018)

Form of Warrant to Purchase Shares of Common Stock (Filed With SEC on February 13, 2018)

Common Stock Sales Agreement, dated January 4, 2018, by and between Dar Bioscience, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on January 4, 2018)

License Agreement dated March 19, 2017, between Dar Bioscience Operations, Inc. and ADVA-Tec, Inc (Filed With SEC on November 13, 2017)

Employment Offer Letter by and between Dar Bioscience Operations, Inc. and Sabrina Martucci Johnson dated as of May 31, 2017 (Filed With SEC on November 13, 2017)

Employment Offer Letter by and between Dar Bioscience Operations, Inc. and Lisa Walters-Hoffert dated as of May 31, 2017 (Filed With SEC on November 13, 2017)

Employment Offer Letter by and between Dar Bioscience Operations, Inc. and Mark Walters dated as of May 31, 2017 (Filed With SEC on November 13, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on August 18, 2017)

LEASE TERMINATION AGREEMENT (Filed With SEC on June 1, 2017)

FIRST AMENDMENT OF LEASE (Filed With SEC on March 31, 2017)

STOCKPURCHASE AGREEMENT by and among CERULEAN PHARMA INC., DARÉ BIOSCIENCE, INC. THE STOCKHOLDERS OF DARÉ BIOSCIENCE, INC. and SOLELY IN SUCHPERSONS CAPACITY AS STOCKHOLDER... (Filed With SEC on March 20, 2017)

ASSET PURCHASE AGREEMENT (Filed With SEC on March 20, 2017)

SUPPORT AGREEMENT (Filed With SEC on March 20, 2017)

LICENSE AGREEMENT (Filed With SEC on March 20, 2017)

- 2 - (Filed With SEC on March 20, 2017)

Cerulean Pharma Inc. | 35Gatehouse Drive | Waltham, MA 02451 | P: 781 ###-###-#### | F: 844-894-CERU (Filed With SEC on March 20, 2017)

SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on November 3, 2016)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on November 3, 2016)

SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on August 4, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on March 10, 2016)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on March 10, 2016)

SEPARATION AGREEMENT (Filed With SEC on November 16, 2015)

CONSULTING AGREEMENT (Filed With SEC on November 16, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on November 16, 2015)

LEASE OF PREMISES AT 35 GATEHOUSE DRIVE, WALTHAM, MASSACHUSETTS FROM ASTRAZENECA PHARMACEUTICALS LIMITED PARTNERSHIP TO CERULEAN PHARMA INC. TABLE OF CONTENTS (Filed With SEC on August 6, 2015)

CONSULTING AGREEMENT (Filed With SEC on August 6, 2015)

TRANSITION AND SEPARATION AGREEMENT (Filed With SEC on August 6, 2015)

CERULEAN PHARMA INC. (a Delawarecorporation) [] Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 30, 2015)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 30, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on March 19, 2015)

FIFTH AMENDMENT (Filed With SEC on March 19, 2015)

AMENDMENT TO SEPARATION, TRANSITION, AND RELEASE OF CLAIMS AGREEMENT (Filed With SEC on March 4, 2015)

WARRANT To Purchase Shares ofthe Common Stock of CERULEAN PHARMA INC. Dated as of January 8, 2015 (the Effective Date) (Filed With SEC on January 8, 2015)

LOAN AND SECURITY AGREEMENT (Filed With SEC on January 8, 2015)

STOCK PURCHASE AGREEMENT (Filed With SEC on January 8, 2015)

CERULEAN PHARMA INC. 840Memorial Drive Cambridge, Massachusetts 02139 (Filed With SEC on January 8, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on November 13, 2014)

AMENDMENT TO STOCK OPTION AGREEMENT AND TERMINATION OF CONTINGENT CONSIDERATION AWARD (Filed With SEC on November 13, 2014)

AMENDMENT NO. 03 DatedSeptember 19, 2014 TO that certain Loan and Security Agreement No. 2161 dated as of December 6, 2011, as amended from time to time, (Agreement), by and... (Filed With SEC on November 13, 2014)

SEPARATION, TRANSITION, AND RELEASE OF CLAIMS AGREEMENT (Filed With SEC on October 30, 2014)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on August 12, 2014)

RIVERSIDE TECHNOLOGY CENTER SECOND LEASE AMENDMENT AS TO THE LEASE BETWEEN RIVERTECH ASSOCIATES II LLC AND CERULEAN PHARMA INC. (Filed With SEC on July 17, 2014)

CERULEAN PHARMA INC. (a Delawarecorporation) [] Shares of Common Stock FORM OF UNDERWRITING AGREEMENT (Filed With SEC on March 31, 2014)

Additional abbreviations may also be used though not in the above list. (Filed With SEC on March 31, 2014)

CERULEAN PHARMA INC. 2014STOCK INCENTIVE PLAN (Filed With SEC on March 31, 2014)

CERULEAN PHARMA INC. INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER 2014 STOCK INCENTIVE PLAN (Filed With SEC on March 31, 2014)

CERULEAN PHARMA INC. NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER 2014 STOCK INCENTIVE PLAN (Filed With SEC on March 31, 2014)

CERULEAN PHARMA INC. 2014EMPLOYEE STOCK PURCHASE PLAN , 2014 (Filed With SEC on March 31, 2014)

CERULEAN PHARMA INC. (f/k/a Tempo Pharmaceuticals, Inc.) 2007 STOCK INCENTIVE PLAN Amended as of January 30, 20141 (Filed With SEC on March 10, 2014)

CERULEAN PHARMA INC. Incentive Stock Option Agreement Granted Under 2007 Stock Incentive Plan (Filed With SEC on March 10, 2014)

CERULEAN PHARMA INC. Nonstatutory Stock Option Agreement Granted Under 2007 Stock Incentive Plan (Filed With SEC on March 10, 2014)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT (Filed With SEC on March 10, 2014)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on March 10, 2014)

SECOND SERIES D CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT CERULEAN PHARMA INC. November 30, 2012 TABLE OF CONTENTS (Filed With SEC on March 10, 2014)

INDENTURE OF LEASE by and between RIVERTECH ASSOCIATES II, LLC (LESSOR) and CERULEANPHARMA INC. (LESSEE) RIVERSIDE TECHNOLOGY CENTER 840 Memorial Drive Cambridge, Massachusetts... (Filed With SEC on March 10, 2014)

LOAN AND SECURITY AGREEMENT (Filed With SEC on March 10, 2014)

INDEMNIFICATION AGREEMENT (Filed With SEC on March 10, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on March 10, 2014)

WARRANT TO PURCHASE STOCK (Filed With SEC on March 10, 2014)

CERULEAN PHARMA INC. Stock Purchase Warrant (Filed With SEC on March 10, 2014)

PREFERRED STOCK PURCHASE WARRANT Shares of Series D Convertible Preferred Stock Subject to determination as set for the below CERULEAN PHARMA INC. Effective as of December 6, 2011... (Filed With SEC on March 10, 2014)

Cerulean Pharma Inc. 840 MemorialDrive Cambridge, MA 02139 (Filed With SEC on March 10, 2014)

Cerulean Pharma Inc. Change in Control Severance Plan (Filed With SEC on March 10, 2014)

Category

Industry

Companies

Contracts

Dare Bioscience, Inc. Contracts & Agreements